Children are not small adults — growing tissues, smaller body size, and decades of expected life span drive unique priorities in pediatric radiation therapy.
Special populations
Pediatric radiation therapy
The role of radiation therapy in children: why developing tissues demand different priorities, the cancers it treats, the conformal techniques used (including protons), and the late effects that shape lifelong survivorship. Tap a card to expand the detail.
14 topics
Radiation plays a curative role across pediatric CNS tumors, sarcomas, and selected solid tumors, often combined with chemotherapy and surgery.
Modern pediatric treatment favors the most conformal technique available to spare developing normal tissues, with proton therapy increasingly preferred.
Daily reproducibility requires immobilization that a young child can tolerate; anesthesia is common in very young or uncooperative patients.
Because children survive decades after treatment, late effects drive long-term follow-up; the Children's Oncology Group (COG) guidelines structure surveillance.
Brain irradiation in children, especially when young, produces progressive cognitive decline that worsens over years and is dose- and volume-dependent.
Radiation to the hypothalamic-pituitary axis, thyroid, and gonads frequently causes hormone deficits that may emerge years later.
Irradiation of growing bones and vertebrae can stunt growth and distort symmetry, with effects that become visible over years.
Radiation-induced second cancers are a leading cause of late mortality in pediatric cancer survivors; risk depends on dose, volume, age, and genetic predisposition.
Pediatric normal-tissue tolerances are stricter than adult values and increasingly stratified by age; published atlases (QUANTEC, pediatric supplements) guide planning.
Pediatric radiation therapy is delivered by a multidisciplinary team with strong family involvement, from consent through long-term survivorship.
Pediatric radiation is delivered according to risk-adapted, disease-specific protocols that balance dose, volume, and combined-modality therapy to maximize cure while limiting late effects.
Infants and young children who cannot cooperate with a reproducible, immobile setup receive daily procedural sedation — most often propofol — with full anesthesia support, monitoring, and recovery built into the treatment slot.
Smaller bodies, developing tissues, and cooperation challenges require pediatric-specific immobilization, shielding, monitoring, and motion-management equipment sized and adapted for children.